期刊文献+

人肺腺癌吉非替尼耐药细胞系A549/GR的建立及小白菊内酯逆转耐药机制研究 被引量:7

Establishment of the gefitinib-resistant A549/GR cell line of humam lung adenocarcinoma and investigation of the mechanism of parthenolide in reversing drug resistance
下载PDF
导出
摘要 目的建立人肺腺癌吉非替尼耐药细胞系A549/GR,研究其耐药机制,探讨小白菊内酯(PAR)逆转A549/GR耐药的机制。方法以吉非替尼为诱导剂,人肺腺癌细胞系A549为诱导对象,采用大剂量冲击和逐步增加剂量相结合的方法,诱导建立人肺腺癌吉非替尼耐药细胞系A549/GR。采用细胞毒实验(MTT)法测定细胞耐药指数,免疫印迹法(Western blotting)检测细胞耐药相关蛋白表达水平,进一步通过MTT法检测PAR对A549/GR的逆转倍数,Annexin V-FITC双标法检测PAR的促凋亡作用,Western blotting检测细胞凋亡相关蛋白表达水平。结果所建立的人肺腺癌吉非替尼耐药细胞系A549/GR耐药指数为18.7。A549/GR细胞中MDR和ABCG2耐药相关蛋白表达水平较A549升高。MTT结果显示PAR对耐药细胞A549/GR的逆转倍数为8.66。Annexin V-FITC凋亡检测结果显示PAR能有效促进A549/GR细胞凋亡,Western blotting检测显示PAR能有效降低survivin、Bcl-2两种抑制凋亡相关蛋白的表达。结论成功建立了人肺腺癌吉非替尼耐药细胞系A549/GR;PAR通过促进A549/GR细胞凋亡有效逆转其耐药。 Objective To establish a gefitinib resistant cell line A549/GR of human lung adenocarcinoma and investigate the mechanism of drug resistance.Then,to find a reversal agent parthenolide to reverse A549/GR drug resistance.Methods The gefitinib resistant cell line A549/GR was established by a method of repeated treatment with high dose of gefitinib for a short period and followed by low but gradually increasing concentrations of the drug.The drug resistance index was determined by MTT assay,and the expression levels of drug resistant related protein MDR and ABCG2 were detected by the Western blotting assay.The reversal factor of parthnolide in A549/GR cells was measured by MTT assays.The cell apoptosis was detected by AnnexinV FITC staining and the apoptosis related proteins surviving and Bcl-2 were detected by Western blotting analysis.Results The resistance index of A549/GR to gefitinib was 18.7.The expression levels of the drug resistance-related protein MDR and ABCG2 were obviously increased in A549/GR cells.Parthenolide effectively reversed drug resistance of A549/GR,with a reversal factor 8.66.Importantly,parthenolide potently induced A549/GR cell apoptosis and inhibited expression of anti-apoptotic protein surviving and Bcl-2.Conclusion A drug-resistant cell line A549/GR expressing typical drug-resistant proteins was established.Parthenolide can reverse the drug-resistant cells by inducing apoptosis of A549/GR cells.
出处 《重庆医学》 CAS CSCD 北大核心 2012年第35期3689-3691,3694,共4页 Chongqing medicine
基金 国家重点基础发展计划(973计划)项目(2010CB529401)
关键词 肺肿瘤 抗药性 细胞凋亡 逆转剂 靶向治疗 lung neoplasms drug resistance apoptosis revesal agent targeted therapy
  • 相关文献

参考文献12

  • 1Herbst RS, Fukuoka M, Baselga J. Gefitinib a novel targeted approach to treating cancer[J]. Nat Rev Cancer, 2004,4(12) : 956-965.
  • 2刘新垣.癌症靶向治疗的最新进展[J].中华肿瘤防治杂志,2006,13(18):1361-1364. 被引量:19
  • 3Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously trea- ted patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial) [J]. J Clin Oncol, 200a, 21 (12) : 2237- 2246.
  • 4Kris MG, Natale RB, Herbst RS, et al. Efficacy of ge- fitinib,an inhibitor of the epidermal growth factor recep- tor tyrosine kinase, in symptomatic patients with non- small cell lung cancer., a randomized trial[J]. JAMA, 2003,290(16) :2149-2158.
  • 5陈杰,钱桂生,黄桂君,熊玮.人肺腺癌多药耐药细胞系的建立及其生物学特征[J].第三军医大学学报,2001,23(2):135-137. 被引量:17
  • 6Rho JK, Choi YJ, Lee JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib de- termines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line[J]. Lung Cancer,2009,63(2):219-226.
  • 7Biedler JL,Riehm H. CeIlular resistance to actinomycin D in Chinese hamster cells in vitro : cross-resistance, radioau- tographic, and cytogenetic studies [J]. Cancer Res, 1970, 30(4) :1174-1184.
  • 8Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants [J].Biochim Biophys Acta, 1976,455 (1) : 152-162.
  • 9Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant humancells[J]. Cell, 1986,47(3) :381-389.
  • 10Robey RW, Polgar O, Deeken J, et al. ABCG2.. determi- ning its relevance in clinical drug resistance[J]. Cancer Metastasis Rev,2007,26(1) :39-57.

二级参考文献19

  • 1刘新垣.肿瘤抗体治疗与基因抗体治疗的前景[J].中华医学杂志,2004,84(14):1145-1146. 被引量:3
  • 2郭明高,姜明红,杨琴,李月敏,崔贞福,李林芳,吴孟超,钱其军.腺病毒介导的全抗体基因治疗卵巢癌的实验研究[J].中华医学杂志,2004,84(14):1147-1151. 被引量:16
  • 3刘新垣.肿瘤的靶向双基因-病毒治疗策略[J].中华肿瘤杂志,2004,26(8):449-450. 被引量:1
  • 4Xin Yuan Liu,Jin Fa Gu.Targeting gene-virotherapy of cancer[J].Cell Research,2006,16(1):25-30. 被引量:15
  • 5Guzman M L,Rossi R M,Karnischky L,et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenousleukemia stenl and progenitor cells [J]. Blood, 2005,105( 11 ) :4163-4169.
  • 6Wei W,Adachi M,Kawamura R,et al. Parthenolide induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on eatalase activity [ J ]. Apoptosis, 2006, 11 ( 12 ) : 2225-2235.
  • 7Kim J H, Liu L, Lee S O, et al. Suseeptibility of cholangiocarcinoma cells to parthenolide induced apoptosis [J]. Cancer Res, 2005,65 : 6312-320.
  • 8Park J H, Iju L, Kim I H, et al. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells [J]. Cancer Res, 2005, 65(7) :2804-2814.
  • 9Jin Z J. Addition in drug combination [J]. Acta Phannaeol Sin, 1980,1(2): 70.
  • 10Knight D -'. Feverfew:chemistry and biological activity[J].Nat Prod Rep, 1995,12(3) : 271-276.

共引文献43

同被引文献112

引证文献7

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部